O
OneMedNet Corp
ONMDCIK 0001849380NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthServices-Commercial Physical & Biological ResearchDelawareFY ends Dec 31
Period
FY 2024
Revenue
—
Net Income
—
Total Assets
—
Equity
—
Shares Out
54.43M
Op. Cash Flow
—
Business
OneMedNet Corp provides curated, regulatory-grade imaging Real World Data (iRWD) by aggregating de-identified clinical images and patient records from a federated network of healthcare providers. The company delivers multi-stratified datasets to pharmaceutical, biotech, medical device, and AI companies for drug development, product validation, and regulatory submissions. OneMedNet serves life sciences companies and healthcare regulators globally, leveraging AI/ML indexing and clinical expert curation to ensure FDA and international regulatory compliance.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 1 | 643,000 | 1 | 1 | — | |
| Cost of revenue | 2 | 924,000 | 1 | 2 | — | |
| Gross margin | −503,000 | −281,000 | −129,000 | −360,690 | — | |
| General and administrative | 6 | 7 | 4 | 9 | — | |
| Sales and marketing | 1 | 830,000 | 1 | 957,690 | — | |
| Research and development | 2 | 1 | 2 | 952,701 | — | |
| Total operating expenses | 9 | 9 | 7 | 11 | — | |
| Loss from operations | −10 | −10 | −7 | −11 | −585,405 | |
| Interest expense | 67,000 | 147,000 | 11,000 | — | — | |
| Change in fair value of warrants | 56,000 | −9,000 | −129,000 | −4 | 6 | |
| Change in fair value of convertible notes | −1 | 808,000 | 18 | — | — | |
| Change in fair value of crypto assets Bitcoin | 945,000 | −798,000 | — | — | — | |
| Realized gain on sale of crypto assets Bitcoin | −922,000 | −120,000 | — | — | — | |
| Change in fair value of SEPA derivative liabilities | −216,000 | 434,000 | — | — | — | |
| Gain on troubled debt restructurings | −6 | — | — | — | — | |
| Loss on extinguishment of debt | 41,000 | — | — | — | — | |
| Other expense | 16,000 | 60,000 | 34,000 | — | — | |
| Total other (income) expense, net | −7 | 522,000 | 27 | −5 | −625,059 | |
| Loss before income taxes | −3 | −10 | −34 | 551,508 | 5 | |
| Income tax expense | 1,000 | 2,000 | 18,000 | 214,850 | — | |
| Net loss | −3 | −10 | −34 | −6 | 5 | |
| Basic net loss per common share outstanding | −0.06 | −0.36 | −4.65 | — | — | |
| Diluted net loss per common share outstanding | −0.06 | −0.36 | −4.65 | 0.03 | 0.44 | |
| Basic weighted average number of common shares outstanding | 45 | 28 | 7 | — | — | |
| Diluted weighted average number of common shares outstanding | 45 | 28 | 7 | — | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 600,000 | 172,000 | 47,000 | 301,730 | 453,151 | |
| Investment in crypto assets Bitcoin | 506,000 | 3 | — | — | — | |
| Accounts receivable, net | 495,000 | 213,000 | 152,000 | 18,975 | — | |
| Prepaid expenses and other current assets | 509,000 | 385,000 | 166,000 | 100,945 | — | |
| Total current assets | 2 | 4 | 365,000 | 30 | 536,212 | |
| Property and equipment, net | 56,000 | 108,000 | 99,000 | 83,097 | — | |
| Total assets | 2 | 4 | 464,000 | 30 | 118 | |
| Accounts payable and accrued expenses | 3 | 6 | 5 | 3 | — | |
| Deferred revenues | 389,000 | 561,000 | 254,000 | 183,683 | — | |
| Loans payable | 754,000 | 4 | 3 | — | — | |
| Loans payable related parties | — | 2 | — | — | — | |
| Convertible notes at fair value | — | 3 | — | — | — | |
| Deferred underwriter fee payable | — | 3 | 4 | — | — | |
| SEPA put option liability | 186,000 | — | — | — | — | |
| Total current liabilities | 5 | 19 | 14 | 12 | 289,980 | |
| Loans payable, net of current portion | 220,000 | — | — | 3 | — | |
| Warrant liabilities | 71,000 | 15,000 | 24,582 | 362,558 | 5 | |
| SEPA put option liability, net of current portion | — | 434,000 | — | — | — | |
| Total liabilities | 5 | 20 | 14 | 21 | 9 | |
| Commitments and contingencies (Note 13) | — | — | — | 29 | — | |
| Preferred Stock, par value $0.0001, 1,000,000 authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common Stock, par value $0.0001, 100,000,000 shares authorized, 52,172,219 shares issued and 51,984,474 shares outstanding at December 31, 2025, and 28,175,172 shares issued and 27,987,427 shares outstanding at December 31, 2024 | 2,000 | 2,000 | 2,000 | 455 | — | |
| Additional paid-in-capital | 102 | 86 | 78 | 24 | — | |
| Treasury stock, at cost, 187,745 shares at December 31, 2025 and 2024 | −529,000 | −529,000 | — | — | — | |
| Accumulated deficit | −104 | −102 | −91 | −44 | −9 | |
| Total stockholders deficit | −3 | −16 | −13 | −26 | 14 | |
| Total liabilities and stockholders deficit | 2 | 4 | 464,000 | 30 | 118 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 65,000 | 57,000 | 28,000 | 24,807 | — | |
| Stock-based compensation expense | 2 | 628,000 | 1 | 2 | 0 | |
| Stock warrant expense | — | 35,000 | 9 | — | — | |
| Non-cash SEPA commitment fee | — | 500,000 | — | — | — | |
| Gain on forgiveness of CEBA loan | — | −15,000 | — | — | — | |
| Non-cash interest | 45,000 | 121,000 | 11,000 | — | — | |
| Accounts receivable | −282,000 | −61,000 | −133,000 | 72,767 | — | |
| Prepaid expenses and other current assets | 194,000 | 84,000 | −43,000 | — | — | |
| Accounts payable and accrued expenses | 366,000 | 1 | 717,000 | 2 | — | |
| Deferred revenues | −172,000 | 307,000 | 70,000 | — | — | |
| Net cash used in operating activities | −8 | −7 | −5 | 87 | −378,487 | |
| Purchases of property and equipment | −13,000 | −51,000 | −44,000 | −58,137 | — | |
| Purchases of crypto assets Bitcoin | −3 | −3 | — | — | — | |
| Proceeds from sales of crypto assets Bitcoin | 5 | 969,000 | — | — | — | |
| Net cash provided by (used in) investing activities | 2 | −2 | −44,000 | −2 | −117 | |
| Proceeds from private placements, net of issuance costs | 2 | 6 | — | — | — | |
| Proceeds from related party subscription agreements, net of issuance costs | 2 | — | — | — | — | |
| Proceeds from Yorkville SEPA | 3 | — | — | — | 78,925 | |
| Proceeds from exercises of Helena Termination Warrants | 60,000 | — | — | — | — | |
| Repayment of deferred underwriter fees | −500,000 | −100,000 | — | — | — | |
| Repayment of Yorkville Note | −262,000 | — | — | — | −78,925 | |
| Repayment of loans payable | −401,000 | −231,000 | — | — | — | |
| Payment of issuance costs in connection with non-cash conversions of liabilities | −19,000 | — | — | — | −446,112 | |
| Proceeds from issuance of shareholder loans | — | 2 | 454,000 | — | — | |
| Proceeds from issuance of Yorkville Note, net of issuance costs | — | 1 | — | — | — | |
| Proceeds from line of credit borrowings | — | 500,000 | — | — | — | |
| Repayment of CEBA loan | — | −30,000 | — | — | — | |
| Repayment of shareholder loan | — | −200,000 | — | — | — | |
| Repayment of line of credit borrowings | — | −500,000 | — | — | — | |
| Net cash provided by financing activities | 6 | 9 | 5 | −88 | 118 | |
| Net increase in cash and cash equivalents | 413,000 | 125,000 | −224,000 | −850,741 | 453,151 | |
| Cash paid for interest | 23,000 | 26,000 | — | — | — | |
| Cash paid for taxes | 1,000 | 18,000 | — | — | — | |
| Issuance of common stock in connection with settlement of vendor payable | 111,000 | 242,000 | — | — | — | |
| Issuance of common stock upon partial conversions of Yorkville Note | 1 | — | — | — | — | |
| Issuance of common stock upon conversions of loans with related parties | 2 | — | — | — | — | |
| Issuance of common stock upon conversion of PIPE Notes | 510,000 | — | — | — | — | |
| Issuance of common stock upon conversion of loan extensions with related parties | 3 | — | — | — | — | |
| Insurance premium settled by issuance of note payable | 317,000 | 318,000 | — | — | — | |
| Common stock repurchase consideration in loans payable | 312,000 | 329,000 | — | — | — | |
| Common shares issued to partially settle deferred underwriter fees | — | 242,000 | — | — | — | |
| Recognition of prepaid forward contract in exchange for partial conversion of Yorkville Note | — | 343,000 | — | — | — | |
| Extinguishment of officer accrued salaries reclassified to additional paid-in capital | — | 132,000 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is OneMedNet Corp's CIK number?
OneMedNet Corp's SEC CIK number is 0001849380 (1849380). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find OneMedNet Corp's SEC filings?
All of OneMedNet Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.